Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-12-12
2006-12-12
O'Sullivan, Peter (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S224800, C514S225200, C514S225500, C514S226200
Reexamination Certificate
active
07148216
ABSTRACT:
The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient two compounds simultaneously or within 14 days of each other in amounts sufficient to treat the patient.
REFERENCES:
patent: 2645640 (1953-07-01), Charpentier et al.
patent: 5104858 (1992-04-01), Hait et al.
patent: 5428051 (1995-06-01), Tidwell et al.
patent: 5443962 (1995-08-01), Draetta et al.
patent: 5521189 (1996-05-01), Boykin et al.
patent: 5602172 (1997-02-01), Boykin et al.
patent: 5643935 (1997-07-01), Dykstra et al.
patent: 5723495 (1998-03-01), Hall et al.
patent: 5770585 (1998-06-01), Kaufman et al.
patent: 5770593 (1998-06-01), Grunicke et al.
patent: 5843980 (1998-12-01), Hall et al.
patent: 6008247 (1999-12-01), Boykin et al.
patent: 6025398 (2000-02-01), Hall et al.
patent: 6172104 (2001-01-01), Tidwell et al.
patent: 6214883 (2001-04-01), Hall et al.
patent: 6280768 (2001-08-01), McDevitt
patent: 6326395 (2001-12-01), Tidwell et al.
patent: 6569853 (2003-05-01), Borisy et al.
patent: 6642221 (2003-11-01), Uckun et al.
patent: 6693125 (2004-02-01), Borisy et al.
patent: 6846816 (2005-01-01), Borisy et al.
patent: 2003/0114703 (2003-06-01), Leblanc et al.
patent: 2003/0144338 (2003-07-01), Matsumoto et al.
patent: 2003/0161893 (2003-08-01), Yi
patent: 2004/0063769 (2004-04-01), Borisy et al.
patent: 2004/0116407 (2004-06-01), Borisy et al.
patent: 2005/0054708 (2005-03-01), Nichols et al.
patent: 2005/0080075 (2005-04-01), Nichols et al.
patent: 2005/0100508 (2005-05-01), Nichols et al.
patent: 2005/0137185 (2005-06-01), Lee et al.
patent: 2005/0158320 (2005-07-01), Nichols et al.
patent: 681780 (1993-05-01), None
patent: 1288376 (1972-09-01), None
patent: WO 99/46237 (1999-09-01), None
patent: WO 01/35935 (2001-05-01), None
Akiyama et al., “Circumvention of Multiple-Drug Resistance in Human Cancer Cells by Thioridazine, Trifluoperazine, and Chlorpromazine,”J. Natl. Cancer Inst. 76:839-844 (1986).
Al-Abdely et al., “Efficacies of KY62 AgainstLeishmania amazonensisandLeishmania donovaniin Experimental Murine Cutaneous Leishmaniasis and Visceral Leishmaniasis,”Antimicrob. Agents Chemother. 42:2542-2548 (1998).
Andres et al., “Biochemical Effects of Chlorpromazine on Mouse Neuroblastoma Cells,”Vet. Hum. Toxicol. 41:273-278 (1999).
Anees et al., “Inhibition of a Tumor Protease with 3,4-Dichloroisocoumarin, Pentamidine-Isethionate and Guanidino Derivatives,”J. Enzyme Inhibition8:213-221 (1994).
Bailly et al., “Sequence-Specific DNA Minor Groove Binders. Design and Synthesis of Netropsin and Distamycin Analogues,”Bioconjug. Chem. 9:513-538 (1998).
Bailly et al., “Sequence-Selective Binding to DNA of bis(amidinophenoxy) Alkanes Related to Propamidine and Pentamidine,”Biochem. J. 323:23-31 (1997).
Barak et al., “The Effect of Chlorpromazine and Haloperidol on DNA Transcription,”Int. Clin. Psychopharmacol. 11:193-197 (1996).
Barancik et al., “Reversal effects of Several Ca2+ Entry Blockers, Neuroleptics and Local Anesthetics on P-Glycoprotein Mediated Vincristine Resistance of L1210/VCR Mouse Leukaemic Cell Line,”Drugs Exptl. Clin. Res. 20:13-18 (1994).
Barrett et al., “Anti-Sleeping Sickness Drugs and Cancer Chemotherapy,”Parasitology Today16:7-9 (2000).
Bebawy et al., “Selective Modulation of P-Glycoprotein-Mediated Drug Resistance,”Brit J. Cancer85:1998-2003 (2001).
Beckett et al., “Metabolism of Chlorpromazine and Promazine in vitro: Isolation and Characterization of N-Oxidation Products,”Xenobiotica18:61-74 (1988).
Bell et al., “Structure-Activity Relationships of Pentamidine Analogs AgainstGiardia lambliaand Correlation of Antigiardial Activity with DNA-Binding Affinity,”Antimicrob. Agents Chemother. 35:1099-1107 (1991).
Benalm et al., “A Calmodulin-Stimulated Ca 2+ Pump in Plasma-Membrane Vesicles fromTrypanosoma brucel; Selective Inhibition by Pentamidine,”Biochem J296:759-63 (1993).
Bleeker et al., “The Effects of Dexamethazone and Chlorpromazine on Tumor Necrosis Factor-Alpha, Interleukin-1 Beta, Interleukin-1 Receptor Antagonist and Interleukin-10 in Human Volunteers,”Immunology91:548-552 (1997).
Bornstein et al., “An Evalution of the Mechanism of Action of Pentamidine Isethionate,”Journal of Surgical Oncology2:393-398 (1970).
Borsa et al., “Selective Cytotoxicity of Calmidazolium and Trifluoperazine For Cycling Verses Noncycling C3H10T1/2 cells In Vitro,”Cancer Res. 46:133-136 (1986).
Chen et al., “Anti-Tumor Necrosis Factor Properties of Non-Peptide Drugs in Acute-Phase Responses,”Eur. J. Pharmacol. 271:319-327 (1994).
Clancy et al., “Chlorpromazine Modulates Cytokine Expression in the Liver and Lung After Burn Injury and Endotoxemia,”J. Trauma48:215-222 (2000).
Corsini et al., “Induction of Tumor Necrosis Factor-Alpha In Vivo by a Skin Irritant, Tributytin, Through Activation of Transcription Factors: Its Pharmacological Modulation by Anti-Inflammatory Drugs,”J. Invest. Dermatol. 108:892-896 (1997).
Cresson et al., “In Vitro Inhibition of Human Sarcoma Cells' Invasive Ability by Bis(5-Amidino-2-Benzimidazolyl) Methane—a novel esteroprotease inhibitor,”Am. J. Pathol. 123:46-56 (1986).
Cubria et al., “Aromatic Diamidines are Reversible Inhibitors of Porcine Kidney Diamine Oxidase,”Biochem. Pharmacol. 45:1355-1357 (1993).
Darkin et al., “Chlorpromazine: A Potential Anticancer Agent?,”Biochem. Biophys. Res. Commun. 125:184-191 (1984).
Dautzenberg et al., “Pentamidine Aerosol in the Preventive Treatment of Pneumocystosis in AIDS Patients. Comparison of Two Salts and Two Nebulizers,”Presse. Med. 20: 1117-1120 (1991).
Del Poeta et al., “Structure—In Vitro Activity Relationships of Pentamidine Analogues and Dication-Substituted Bis-Benzimidazoles as New Antifungal Agents,”Antimicrob. Agents Chemother. 42:2495-2502 (1998).
Driscoll et al., “Pyschotropic Drugs as Potential Antitumor Agents: A Selective Screening Study,”Cancer Treatment Rep. 62:45-74 (1978).
Ferronl et al., “N1-Substituted Benzamidines: Synthesis, Antiproteinase Activity and Inhibition of Tumor Cell Growth,”Il Farmaco46:1311-1321 (1991).
Fibach et al., “Phorbol Ester-Induced Adhesion of Murine Erythroleukemia Cells: Possible Involvement of Cellular Proteases,”Carcinogenesis, 4:1395-1399, 1983.
Fimognari et al., “Flow Cytometric Analysis of Genetic Damage, Effect on Cell Cycle Progression, and Apoptosis by Thiophanate-Methyl in Human Lymphocytes,”Environ. Mol. Mutagen. 33:173-176 (1999).
Ferroni et al., “N1-Substituted Benzamidines: Synthesis, Antiproteinase Activity and Inhibition of Tumor Cell Growth,”Farmaco46:1311-1321 (1991).
Ford et al., “Structural Features Determining Activity of Phenothiazines and Related Drugs for Inhibition of Cell Growth and Reversal of Multidrug Resistance,”Molecular Pharmacology35:105-115 (1989).
Frazer et al., “Endo-Exonuclease of Human Leukaemic Cells: Evidence for a Role in Apoptosis,”J. Cell Sci. 109:2343-2360 (1996).
Gambari et al., “DNA-Binding Activity and Biological effects of Aromatic Polyamidines,”Biochem Pharmacol47:599-610 (1994).
Ganapathi et al., “Factors Governing the Modulation of Vinca-Alkalold Resistance in Doxorublcln-Resistant Cells by the Calmodulin Inhibitor Trifluoperazine,”Biochemical Pharmacology35:673-678 (1986).
Hait et al., “Antitumor and Toxic Effects of Combination Chemotherapy with Bleomycin and a Phenothiazine Anticalmodulin Agent,”J. Natl. Cancer Inst. 80:246-250 (1988).
Herberich et al., “Synthesis of a Netropsin Conjugate of a Water-Soluble epi-Quinocarcin Analogue: the Importance of Stereochemistry at Nitrogen,”Bioorganic&Medicinal Chemistry8:523-532 (2000).
Huilgol et al., “Assessment of Chlorpromazine as Rad
Borisy Alexis
Foley Michael A.
Keith Curtis
Stockwell Brent R.
Clark & Elbing LLP
CombinatoRx, Inc.
O'Sullivan Peter
LandOfFree
Combinations of drugs for the treatment of neoplastic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combinations of drugs for the treatment of neoplastic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations of drugs for the treatment of neoplastic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3719312